Biomarin's dwarfism drug receives FDA approval
The growth hormone Voxzogo has been approved by the US Food and Drug Administration (FDA) as a treatment for achondroplasia in children.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Biomarin's drug against achondroplasia, also known as dwarfism, has had a better start than most, and now the US-based biotech company can add another feather to its cap.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
